Safety and Tolerability Study of Drug to Treat Schizophrenia

Completed · Phase 2

Conditions studied: Schizophrenia

In brief

The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.

Key facts

Study ID
NCT00044005
Run by
Sumitomo Pharma America, Inc.
People needed
98
Starts
2002-09-01
Expected to finish
2003-11-01
Last updated by the study team
2014-04-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.